Titrated low-dose amitriptyline (a tricyclic antidepressant) was superior to placebo as a second-line treatment for irritable bowel syndrome (IBS) in primary care according to results from a new randomized, double-blind, placebo-controlled phase III trial (ATLANTIS). Across 55 general practices in England, 463 participants with IBS (mean age 48.5 years; 68% female, 32% male) were randomly assigned to either low-dose amitriptyline (10 mg once daily) or placebo, with dose titration over 3 weeks (up to 30 mg once daily). A statistically significant difference in IBS Severity Scoring System score was observed in the amitriptyline group versus placebo at 6 months (primary outcome; −27.0, 95% CI −46.9 to −7.10; P = 0.0079). Notably, amitriptyline was safe and well tolerated.

根据一项新的随机、双盲、安慰剂对照 III 期试验 (ATLANTIS) 的结果，滴定低剂量阿米替林（一种三环类抗抑郁药）作为初级保健中肠易激综合征 (IBS) 的二线治疗优于安慰剂。 ）。在英格兰 55 个全科诊所中，463 名患有 IBS 的参与者（平均年龄 48.5 岁；68% 女性，32% 男性）被随机分配到低剂量阿米替林（10 毫克，每天一次）或安慰剂组，并在 3 周内逐步调整剂量（每日一次，最多 30 毫克）。6 个月时，阿米替林组与安慰剂组的 IBS 严重程度评分系统评分存在统计学显着差异（主要结果；-27.0，95% CI -46.9 至 -7.10；P =  0.0079）。值得注意的是，阿米替林安全且耐受性良好。